DR STANLEY LAHAM: FLU VACCINES SHOWN IN 2018 TO DO MORE HARM THAN GOOD, BIG PHARMA NEEDS NEW MARKETS

DR STANLEY LAHAM: FLU VACCINES SHOWN IN 2018 TO DO MORE HARM THAN GOOD, BIG PHARMA NEEDS NEW MARKETS
https://politicsthisweek.wordp....ress.com/2021/05/13/

62 million doses of vaccines contaminated - Another 62 million Covid vaccines ‘contaminated’ at scandal-hit factory - Jessica Kwong - An additional 62 million Johnson & Johnson coronavirus vaccine doses could be contaminated at the factory that was forced to toss 15million doses last week because of a production blunder. Quality-control managers at a plant in Baltimore, Maryland, operated by Emergent BioSolutions, are now required to test every batch of Johnson & Johnson vaccines produced alongside 15million doses of AstraZeneca vaccines destroyed after their ingredients were mixed up. That amounts to screening 62million doses for possible contamination, The New York Times reported on Tuesday based on documents and interviews with former workers at the factory and federal officials. Workers at the factory in February unknowingly cross-contaminated about 15million doses of the Johnson & Johnson jab with AstraZeneca doses, rendering them unusable. The error was caught before the doses were distributed. US Food and Drug Administration inspectors plan to closely examine the factory before approving the other 62million doses for release. It is not known if the scrutiny would be completed in time to allow Johnson & Johnson to provide its promised 24million doses to the US government this month. Emergent BioSolutions received $163million through a government contract but had a history of failing quality-control audits, The Times reported.

Dr Stanley Laham, retired immunologist, on Emergent Bio Solutions contamination of vaccines, indemnification of vaccines by governments, how Haiti has had very few Covid deaths, and failure of the flu vaccine over the years. Emergent BioSolutions Stock: Berger Montague Investigates Potential Securities Fraud Claims Against Emergent BioSolutions Inc. (EBS); Lead Plaintiff Deadline is June 18, 2021 Whistleblowers: Persons with non-public information regarding Emergent are encouraged to confidentially assist Berger Montague's investigation or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us. Emergent is a biopharmaceutical company that develops vaccines for infectious diseases. According to a recently filed lawsuit, the Company and senior management failed to disclose a history of manufacturing issues and quality control deficiencies at Emergent's Baltimore facility, and that longstanding contamination risks had resulted in a string of citations by the Food and Drug Administration. On March 31, 2021, media reports revealed that Emergent "mixed up" ingredients for J&J's and AstraZeneca's Covid vaccines, which resulted in up to 15 million doses of J&J's vaccine being contaminated and rendered unusable. On this news, shares declined $14.29 - approximately 15% - over the next two trading days, from a closing price of $92.91 on March 31 to $78.62 on April 5.